ECSP19029758A - Anticuerpos anti-il-33 y usos de los mismos - Google Patents

Anticuerpos anti-il-33 y usos de los mismos

Info

Publication number
ECSP19029758A
ECSP19029758A ECSENADI201929758A ECDI201929758A ECSP19029758A EC SP19029758 A ECSP19029758 A EC SP19029758A EC SENADI201929758 A ECSENADI201929758 A EC SENADI201929758A EC DI201929758 A ECDI201929758 A EC DI201929758A EC SP19029758 A ECSP19029758 A EC SP19029758A
Authority
EC
Ecuador
Prior art keywords
antibodies
bind
agents
useful
treatment
Prior art date
Application number
ECSENADI201929758A
Other languages
English (en)
Inventor
Angela Jeannine Okragly
Stephanie Marie Truhlar
Julian Davies
Robert Jan Benschop
Chetankumar Natvarlal Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP19029758A publication Critical patent/ECSP19029758A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención proporciona anticuerpos los cuales se unen y neutralizan IL-33 humano, y métodos para usar los mismos, tales anticuerpos son útiles como agentes para el tratamiento de condiciones asociadas con enfermedad alérgica que incluye tratar dermatitis atópica.
ECSENADI201929758A 2016-10-28 2019-04-26 Anticuerpos anti-il-33 y usos de los mismos ECSP19029758A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662414258P 2016-10-28 2016-10-28

Publications (1)

Publication Number Publication Date
ECSP19029758A true ECSP19029758A (es) 2019-05-31

Family

ID=60263117

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201929758A ECSP19029758A (es) 2016-10-28 2019-04-26 Anticuerpos anti-il-33 y usos de los mismos

Country Status (37)

Country Link
US (2) US10501536B2 (es)
EP (1) EP3532499B1 (es)
JP (1) JP6830533B2 (es)
KR (1) KR102266144B1 (es)
CN (1) CN109863173B (es)
AR (1) AR109948A1 (es)
AU (1) AU2017351183B2 (es)
BR (1) BR112019005139A2 (es)
CA (1) CA3039232C (es)
CL (1) CL2019001043A1 (es)
CO (1) CO2019003047A2 (es)
CR (1) CR20190179A (es)
CY (1) CY1124360T1 (es)
DK (1) DK3532499T3 (es)
EA (1) EA201990778A1 (es)
EC (1) ECSP19029758A (es)
ES (1) ES2878037T3 (es)
HR (1) HRP20211221T1 (es)
HU (1) HUE055621T2 (es)
IL (1) IL265689B2 (es)
JO (1) JOP20190093A1 (es)
LT (1) LT3532499T (es)
MA (1) MA46619B1 (es)
MD (1) MD3532499T2 (es)
MX (1) MX394799B (es)
PE (1) PE20191045A1 (es)
PH (1) PH12019500929A1 (es)
PL (1) PL3532499T3 (es)
PT (1) PT3532499T (es)
RS (1) RS62120B1 (es)
SI (1) SI3532499T1 (es)
SM (1) SMT202100442T1 (es)
TN (1) TN2019000086A1 (es)
TW (2) TWI676680B (es)
UA (1) UA121293C2 (es)
WO (1) WO2018081075A1 (es)
ZA (1) ZA201901935B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
EP4045641A1 (en) 2019-10-15 2022-08-24 Eli Lilly and Company Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
KR20220092927A (ko) 2019-11-04 2022-07-04 메디뮨 리미티드 신장 장애를 치료하기 위한 항 il-33 치료제
JP7843701B2 (ja) 2019-11-04 2026-04-10 メディミューン リミテッド Ｉｌ－３３アンタゴニストの使用方法
CN113214395A (zh) * 2020-01-21 2021-08-06 迈威(上海)生物科技股份有限公司 抗st2抗体及其应用
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
JP2023516497A (ja) 2020-03-13 2023-04-19 メドイミューン・リミテッド Ｉｌ３３にリスクアレルを有する対象を治療するための治療方法
CN115867575A (zh) 2020-04-06 2023-03-28 免疫医疗有限公司 用il-33轴结合拮抗剂治疗急性呼吸窘迫综合征
WO2021228760A1 (en) 2020-05-11 2021-11-18 Medimmune Limited Formulations of anti-il-33 antibodies
CN111620948B (zh) * 2020-06-10 2022-04-08 南京赛新生物科技有限公司 针对il-33的抗体
CN113603775B (zh) * 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
TW202423973A (zh) 2022-08-19 2024-06-16 英商梅迪繆思有限公司 選擇患者以用ｉｌ—３３軸拮抗劑進行治療之方法
AU2024392535A1 (en) * 2023-11-27 2026-06-04 Glaxosmithkline Intellectual Property Development Limited Il-33 binding antibodies
CN122341639A (zh) 2023-12-07 2026-07-03 免疫医疗有限公司 治疗哮喘的方法
TW202540173A (zh) 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法
WO2025242618A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Bronchiectasis treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
ES2549637T3 (es) * 2011-02-23 2015-10-30 F. Hoffmann-La Roche Ag Anticuerpos contra IL33R humano y la utilización de los mismos
FR2972006B1 (fr) 2011-02-24 2016-03-25 Centre Nat Rech Scient Nouveaux fragments d'il-33 superactifs et leurs utilisations
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) * 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
CA2946511C (en) * 2014-04-21 2023-08-22 The Childen's Hospital Of Philadelphia Compositions and methods for treating cytokine-related disorders
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック， インコーポレイテッド 抗インターロイキン−３３抗体及びその使用
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
AU2017208099A1 (en) 2016-01-14 2018-08-09 Anaptysbio, Inc. Inhibition of allergic reaction using an IL-33 inhibitor
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها

Also Published As

Publication number Publication date
AU2017351183B2 (en) 2020-04-09
JP2019534282A (ja) 2019-11-28
US20200048340A1 (en) 2020-02-13
RS62120B1 (sr) 2021-08-31
IL265689B2 (en) 2024-02-01
EP3532499A1 (en) 2019-09-04
TWI676680B (zh) 2019-11-11
CO2019003047A2 (es) 2019-04-12
TW201920675A (zh) 2019-06-01
LT3532499T (lt) 2021-08-10
ZA201901935B (en) 2020-11-25
TN2019000086A1 (en) 2020-07-15
IL265689A (en) 2019-05-30
EA201990778A1 (ru) 2019-09-30
MX2019004863A (es) 2019-08-12
CA3039232A1 (en) 2018-05-03
IL265689B1 (en) 2023-10-01
PL3532499T3 (pl) 2021-11-08
TW201829459A (zh) 2018-08-16
MD3532499T2 (ro) 2021-09-30
PT3532499T (pt) 2021-07-05
TWI647238B (zh) 2019-01-11
HRP20211221T1 (hr) 2021-10-29
CA3039232C (en) 2021-05-25
CY1124360T1 (el) 2022-07-22
JOP20190093A1 (ar) 2019-04-25
MA46619B1 (fr) 2021-09-30
CN109863173B (zh) 2022-06-03
EP3532499B1 (en) 2021-05-05
CR20190179A (es) 2019-08-26
US10913793B2 (en) 2021-02-09
JP6830533B2 (ja) 2021-02-17
SI3532499T1 (sl) 2021-08-31
DK3532499T3 (da) 2021-06-28
US10501536B2 (en) 2019-12-10
MX394799B (es) 2025-03-24
AU2017351183A1 (en) 2019-04-11
AR109948A1 (es) 2019-02-06
PH12019500929A1 (en) 2019-12-02
US20180118821A1 (en) 2018-05-03
HUE055621T2 (hu) 2021-12-28
CN109863173A (zh) 2019-06-07
PE20191045A1 (es) 2019-08-06
SMT202100442T1 (it) 2021-09-14
ES2878037T3 (es) 2021-11-18
WO2018081075A1 (en) 2018-05-03
CL2019001043A1 (es) 2019-08-30
KR102266144B1 (ko) 2021-06-18
KR20190054160A (ko) 2019-05-21
BR112019005139A2 (pt) 2019-06-04
UA121293C2 (uk) 2020-04-27

Similar Documents

Publication Publication Date Title
CO2019003047A2 (es) Anticuerpos anti-il-33 y usos de los mismos
CY1126255T1 (el) Χρησεις ανταγωνιστων il-13 για την αγωγη της ατοπικης δερματιτιδας
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
MX370506B (es) Método para tratar trastorno de estrés post-traumático.
CL2017001459A1 (es) Biarilo compuestos útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
MX2018014456A (es) Anticuerpos contra alfa-sinucleina y sus usos.
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CL2017001960A1 (es) Métodos de tratamiento de enfermedades inflamatorias
ECSP16075416A (es) Anticuerpos de il-21
MX2018010993A (es) Derivados de icariina e icaritina.
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2018002340A1 (es) Anticuerpos para il-17c
EP3681505C0 (en) IMPROVED TREATMENT OF ATOPIC DERMATITIS USING TRADIPITANT
MX2018012230A (es) Métodos para tratar enfermedades oculares.
CL2018001279A1 (es) Spodoptera frugiperda resistente a vip3a.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos